Japan Real Estate Investment Corp.'s ¥10 Billion Unsecured Bonds Rated 'AA-' Jul 10

  • ID: 1802036
  • July 2010
  • Region: Japan
  • Standard & Poors
1 of 3

TOKYO (Standard & Poor's) July 14, 2010--Standard & Poor's Ratings Services today assigned its 'AA-' rating to Japan Real Estate Investment Corp.'s (JRE; AA-/Negative/A-1+) proposed ¥10 billion Series 8 unsecured bonds, due July 23, 2015. The rating reflects JRE's strong business position, high asset quality, and conservative financial profile. JRE boasts the second-largest asset portfolio among the listed Japanese real estate investment trusts (J-REITs) that focus on office buildings. The company has a strong business position in the J-REIT market and commands high market recognition, backed by the strong brand recognition and credit quality of its sponsors, Mitsubishi Estate Co. Ltd. (Mitsubishi Estate; A+/Stable/A-1), The Dai-ichi Life Insurance Co. Ltd. (A/Negative/--), and Mitsui & Co. Ltd. (A+/Negative/A-1). As of June...

Companies mentioned in this report are:
- Japan Real Estate Investment Corp.

Action: New Rating

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

- Japan Real Estate Investment Corp.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.